KBI Biopharma, a Durham, North Carolina-headquartered biopharmaceutical contract development and manufacturing organization, has partnered with ReForm Biologics, a Cambridge, Massachusetts-headquartered formulation innovator for protein therapeutics, to make biopharmaceutical formulations.

Through this collaboration, KBI and ReForm Biologics plan to help customers extend product lifecycles, enable improved dosing, and enhance manufacturing efficiencies. As part of the strategic partnership, KBI has made an equity investment in ReForm Biologics.

ReForm Biologics’ proprietary excipient technologies are designed to decrease viscosity and enhance stability. As part of the collaboration, KBI will provide services to ReForm Biologics to further develop and validate its biologic formulation platform while also gaining access to ReForm Biologics’ proprietary technology. ReForm Biologics will maintain the ability to use its formulation technologies directly with its pharmaceutical and biotechnology partners.

Financial terms of the agreement were not disclosed.

Source: KBI Biopharma